• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of class actions taken in the quarter regarding marketed unapproved drugs

Dictionary: The Unapproved Drugs initiative is described in detail on FDA Internet. In removing unapproved drugs from the marketplace, OC may issue a class action to all manufacturers and/or individual actions to individual manufacturers. For the initial version of this measure we are reporting on class actions, as well as other actions such as seizures or injunctions.


These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct - Dec 2009N/A1
Jan – Mar 2010N/A1
Apr – Jun 2010N/A1
Jul – Sep 2010N/A1

Number of products involved in class actions taken in the quarter regarding marketed unapproved drugs

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetNumber
Oct - Dec 2009N/A7
Jan – Mar 2010N/A6
Apr – Jun 2010N/A1
Jul – Sep 2010N/AN/A

Number of manufacturers involved in class actions taken in the quarter regarding marketed unapproved drugs

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetNumber
Oct - Dec 2009N/A4
Jan – Mar 2010N/A2
Apr – Jun 2010N/A1
Jul – Sep 2010N/AN/A

Number of seizures or injunctions issued in the quarter for unapproved drugs

Dictionary: The Unapproved Drugs initiative is described in detail on FDA Internet. In removing unapproved drugs from the marketplace, OC may issue a class action to all manufacturers and/or individual actions to individual manufacturers. For the initial version of this measure we are reporting on class actions, as well as other actions such as seizures or injunctions.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct - Dec 2009N/A0
Jan – Mar 2010N/A0
Apr – Jun 2010N/A2
Jul – Sep 2010N/A0

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.